Peptide record

TPDB91246

cyclic dipeptide - 3b ACE inhibitors Antibacterial Anticancer Antifungal Antihypertensive Antioxidant Toxicity iDPPIV modified_plain modified
2 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

Standard-residue backbone model; source-recorded chemical modifications are not verified in these coordinates.

TPDB91246
cyclic dipeptide - 3b
ACE inhibitors Antibacterial Anticancer Antifungal Antihypertensive Antioxidant Toxicity iDPPIV
Anti-infective peptides Cardiometabolic peptides Cancer-related peptides Toxicity and safety peptides Functional / health-promoting peptides
FermFooDB Peptipedia CancerPPD 2.0 CAFPdb dbAMP AHTPDB AHTpin AODB Multi-AOP iDPPIV
modified_plain
Yes
A 2-aa modified multi-activity (ACE inhibitors, Antibacterial, Anticancer, and other sources) peptide sequence curated from FermFooDB, Peptipedia, CancerPPD 2.0, and other sources, with an available 3D structural model.
C-terminal: Cyclized Chemical: L-7dimethylallyl at Trp N-terminal: Cyclized
Sequence
WL
Physicochemical Analysis

Sequence-only estimates are not provided for modified or non-standard source notation. Reported molecular properties, when available, are retained below with their source records.

Chemical Descriptors
2 reviewed residue count
Cyclized Activity
L-7dimethylallyl at Trp Activity
L Activity
Cyclic Activity
Cyclized Activity
Anticancer Activity
Synthetic Activity
Evidence Records 2 records
Evidence 1 Activity

Activity

IC50
IC50 = 85.2 µM
Anticancer
85.2 µM

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT assay
72-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2020

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 41.4 µM
Anticancer
41.4 µM

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT assay
72-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2020